Vigonvita Life Sciences Co., Ltd. Issues Supplemental Announcement on Annual Report for FY2025
Hong Kong, May 22, 2026 – Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630), a joint stock company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange, has issued a supplemental announcement concerning its Annual Report for the year ended December 31, 2025. This supplemental release addresses the confirmation from its independent auditor, Deloitte Touche Tohmatsu, regarding the Group’s continuing connected transactions.
Key Highlights from the Supplemental Announcement
- Independent Auditor’s Confirmation: Deloitte Touche Tohmatsu provided a letter to the Board, confirming they found no evidence to suggest any irregularities regarding the Group’s continuing connected transactions for the reported period. Specifically:
- All such transactions were approved by the Board.
- The transactions were conducted, in all material respects, in accordance with the terms of the relevant agreements.
- The transactions did not exceed the annual caps as disclosed in the Prospectus, regarding the aggregate value of each transaction.
- Scope of Transactions: The transactions in question related to the purchase of active pharmaceutical ingredients (API) and ancillary services by the Group. Importantly, none of these connected transactions involved the provision of goods or services by the Group, but rather were related to purchases by the Group.
- No Changes to Other Information: The Board confirmed that the supplemental information does not affect or modify any other information in the previously published Annual Report. All other disclosures remain unchanged.
- Board Composition: As of the announcement date, the Board comprises Dr. Tian Guanghui (Chairman, Executive Director, CEO, and General Manager), Dr. Hu Tianwen (Executive Director), Mr. Liu Haoxuan (Non-Executive Director), and three independent non-executive Directors: Dr. Ju Dianwen, Ms. Cao Xinwen, and Dr. Xu Hongxi.
Implications for Shareholders and Share Price Sensitivity
- Regulatory Compliance: The confirmation from Deloitte Touche Tohmatsu that the Group’s continuing connected transactions were in compliance with Hong Kong Listing Rules and the Company’s own Prospectus is a critical positive signal. This helps to mitigate potential regulatory or reputational risks that could negatively impact share value.
- Operational Transparency: By providing this supplemental information, the Company reinforces its commitment to transparency and good governance, which is generally supportive of investor confidence and could have a stabilising or positive effect on the share price.
- No Unauthorised Transactions or Over-cap: The explicit confirmation that no annual caps were exceeded and no unauthorised transactions occurred removes uncertainty regarding possible financial or compliance breaches, which could otherwise have been price-sensitive negative news.
- Nothing Adverse or Unexpected: The supplemental announcement confirms that there are no new adverse developments or restatements, and no matters have come to the auditor’s attention that would require concern from shareholders.
Investors should note that while this supplemental announcement does not introduce new business developments, it serves as an important assurance of the Company’s compliance and internal controls—key factors that support long-term shareholder value and reduce risk of negative surprises.
Disclaimer: The information provided in this article is based on the Company’s official supplemental announcement and is intended for informational purposes only. It does not constitute investment advice. Investors are advised to conduct their own research or consult their financial adviser before making investment decisions.
維健維他生命科學股份有限公司 2025年度報告補充公告
香港，2026年5月22日 — 維健維他生命科學股份有限公司（股份代號：2630），一家於中華人民共和國註冊成立並於香港聯交所上市的股份有限公司，就截至2025年12月31日止年度年報發佈補充公告。此補充公告主要回應獨立核數師德勤發出的有關集團持續關連交易的確認函。
補充公告重點摘要
- 獨立核數師確認： 德勤會計師事務所向董事會發函，確認在審閱集團於報告期內的持續關連交易時，並無發現任何令他們相信相關交易存在不合規之處，包括：
- 所有交易均已獲董事會批准。
- 交易在所有重大層面上均根據相關協議執行。
- 交易金額未有超出公司招股章程所披露的年度上限。
- 交易範圍： 有關交易涉及集團購買原料藥（API）及相關配套服務。值得注意的是，這些關連交易並不涉及集團向外提供貨品或服務，只涉及集團的採購行為。
- 其他資料無更改： 董事會確認，補充公告內容不影響或更改年報中任何其他資料，所有其他披露內容保持不變。
- 董事會組成： 截至公告日，董事會成員包括：田光輝博士（董事長、執行董事、行政總裁及總經理）、胡天文博士（執行董事）、劉浩軒先生（非執行董事），以及三位獨立非執行董事：居典文博士、曹新文女士、徐紅喜博士。
對股東及股價敏感事項的影響
- 合規性確認： 德勤的確認函證明集團在持續關連交易方面遵守香港上市規則及招股章程的披露，這對減低監管或聲譽風險有重要正面作用。
- 提升透明度： 公司主動補充披露，增強透明度及良好管治，有助於提升投資者信心，對股價有穩定或正面影響。
- 無違規或超標交易： 明確指出並無超過年度上限或未經授權交易，消除潛在的財務或合規負面消息。
- 無不利或意外事項： 補充公告確認未有新出現的不利發展或需要股東關注的不尋常事項。
投資者需注意，雖然本補充公告未有帶來新業務發展，但它對公司合規性及內部控制提供了關鍵保證，是維持長遠股東價值及降低風險的重要因素。
免責聲明：本文章內容來自公司官方補充公告，僅供參考，並非投資建議。投資者應自行研究或諮詢財務顧問，謹慎作出投資決定。
